Issy-les-Moulineaux, March 25, 2020
Availability of the 2019 Universal Registration Document - Suspension of 2020
Edenred has published its 2019 Universal Registration Document, filed with the
French Financial Markets Authority (Autorité des marchés financiers - AMF) on
March 25, 2020. This document is available on the AMF's website and on
Edenred's website at:
- www.edenred.com, Investors / Shareholders section
- Regulated information section, then Periodic section
The 2019 Universal Registration Document includes:
- the annual financial report (the cross-reference table of which appears on
page 367 of the 2019 Universal Registration Document, to make this
information easier to find);
- the report on corporate governance prepared by the Board of Directors as well
as the related Statutory auditors' findings (pages 124 to 182 and page 268 of
the 2019 Universal Registration Document, respectively); and
- a description of the share buyback program subject to the authorization of
the Combined General Meeting dated May 7, 2020 (page 37 of the 2019 Universal
Paper copies are available at Edenred's registered office (Direction de la
Communication financière, Immeuble Be Issy, 14 - 16 boulevard Garibaldi,
92130 Issy-les-Moulineaux - France).
On February 26, 2020, Edenred published its 2019 annual results and stated its
outlook for full- year 2020. This outlook has been updated due to the
uncertainties linked to the Covid-19 epidemic.
This epidemic will have an impact on the Group's business, the extent of which
is not possible to estimate as at the date this Universal Registration Document
was filed. The impact will depend, among other things, on the duration of the
epidemic, the containment measures implemented by the various countries in
which Edenred operates, and the use of short-time working by some of the
Due to these uncertainties, the Group has suspended its targets for full-year
2020 until it has better visibility of the financial impacts of the epidemic.
The Group is taking appropriate measures to reduce the consequences of the
epidemic on its business and earnings.